Oligomerization Inhibition, Combined With Allosteric Inhibition, Abrogates the Transformation Potential of T315i-Positive BCR/ABL

Leukemia - United Kingdom
doi 10.1038/leu.2009.194
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Broad Spectrum Alkynyl Inhibitors of T315I BCR-Abl

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2010English

Multidomain Targeting of BCR-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2013English

Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571

Clinical Cancer Research
Cancer ResearchOncology
2006English

Inhibition of V-Abl Transformation by P53 and P19ARF

Oncogene
Cancer ResearchGeneticsMolecular Biology
1999English

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL T315I Point Mutation

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2015English

Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2010English

Small Interfering RNA Against BCR-ABL Transcripts Sensitize Mutated T315I Cells to Nilotinib

Haematologica
Hematology
2010English

Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model

Haematologica
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy